The Tumor Microenvironment in Colorectal Cancer: New Therapeutic Targets and Implications for Therapy Response
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 273
Special Issue Editor
Special Issue Information
Dear Colleagues,
Colorectal cancer (CRC) remains one of the deadliest and most commonly diagnosed cancers worldwide. Metastasis is the major cause of death in CRC patients and is often associated with resistance to immunotherapy. Recent studies indicate that tumor cell growth and response to therapy are significantly dependent on the tumor microenvironment (TME). The genetic landscape of the tumor is a critical determinant shaping the composition of the TME. Conversely, in the TME, immune, stromal cells and the microbiota communicate with tumor cells and can drive cancer stemness and immune escape. The mechanisms that orchestrate and maintain the crosstalk between the TME and cancer cells are potentially actionable drug targets to enable novel therapies. This Special Issue aims to publish a collection of cutting-edge research on the TME of CRC using preclinical and clinical studies. I’m pleased to invite you to submit studies that address the establishment of the TME during tumor progression, identify targets that sustain and mediate an immunosuppressive or immunoenhancing TME, and elucidate the role of the TME in cancer therapy response and drug resistance.
In this Special Issue, original research articles and reviews are welcome. I look forward to receiving your contributions.
Dr. Markus Tschurtschenthaler
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colorectal cancer
- tumor microenvironment
- immune and stromal cells
- microbiota
- immunotherapy
- drug resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
